U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758777) titled 'Usability Evaluation of the Intelligent Fingerprinting Drug Screening System' on July 30. ... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More
U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758387) titled 'Polydextrose Functional Gummies for Weight Management in Adults With Overweight or Obesity'... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy ... Read More
U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758699) titled 'Impact of De Quervain's Tenosynovitis on Grip Strength and Quality of Life in Smartphone-Ad... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxe... Read More
Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Ad... Read More